Nicotinic antagonists

Ketamine (CAS 6740-88-1) Global Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 3, 2021
Health, General Health, Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Ketones, Dissociative drugs, NMDA receptor antagonists, Nicotinic antagonists, Ketamine

The "Ketamine (CAS 6740-88-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ketamine (CAS 6740-88-1) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Ketamine.
  • The fifth chapter deals with Ketamine market trends and forecast, distinguish Ketamine manufacturers and suppliers.
  • The Ketamine global market report key points:

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

Retrieved on: 
Thursday, June 3, 2021
Entheogens, Psychoactive drugs, Branches of biology, Drugs, Drug rehabilitation, Nicotinic antagonists, Indole alkaloids, NMDA receptor antagonists, Ibogaine, Tabernanthe iboga, Pharmaceutical industry, Synthetic

Throughout this proof-of-concept stage, MINDCURE completed the chemistry and route scouting and successfully manufactured synthetic ibogaine.

Key Points: 
  • Throughout this proof-of-concept stage, MINDCURE completed the chemistry and route scouting and successfully manufactured synthetic ibogaine.
  • In the coming weeks, MINDCURE will focus on the scale-up process by launching stage two of the manufacturing process for pharmaceutical grade ibogaine.
  • By manufacturing synthetic ibogaine, MINDCURE's research team will have access to a sustainable and high-quality drug supply, ensuring consistent dosing and reliable results.
  • "We have successfully completed the critical first step in our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes," said Kelsey Ramsden, President and CEO of MINDCURE.

Myconic Capital Becomes Ketamine One

Retrieved on: 
Tuesday, June 1, 2021
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Arylcyclohexylamines, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine

VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).

Key Points: 
  • VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) -- Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (Ketamine One or the Company) from Myconic Capital Corp. and do business under the Ketamine One brand (the Name Change).
  • Ketamine Ones board of directors has appointed Dr. Mark Kimmins as the Companys Chief Medical Officer.
  • We are excited to reveal the re-brand of the Company to Ketamine One, which more accurately reflects our vision to quickly become a leader in the delivery of breakthrough mental wellbeing treatments, said Adam Deffett, VP of Capital Markets for Ketamine One.
  • KetamineOne Capital Limited (formerly Myconic Capital Corp.) (NEO: MEDI) is a single-purpose company focused becoming a North American leader in mental health.

PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover Novel Psychedelic Formulations

Retrieved on: 
Thursday, May 27, 2021
Psychoactive drugs, Drugs, Entheogens, Branches of biology, NMDA receptor antagonists, Nicotinic antagonists, Hallucinations, Sedatives, Psychedelic drug, Ketamine, Mescaline, Ibogaine

(MediSynergics), a drug discovery company, to develop MediSynergics patented ketamine derivatives for pain and other CNS disorders and to investigate drug discovery and development of next-generation psychedelic derivatives, such as psilocybin, N,N-Dimethyltryptamine (DMT), 3,4-Methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD), mescaline, and ibogaine.

Key Points: 
  • (MediSynergics), a drug discovery company, to develop MediSynergics patented ketamine derivatives for pain and other CNS disorders and to investigate drug discovery and development of next-generation psychedelic derivatives, such as psilocybin, N,N-Dimethyltryptamine (DMT), 3,4-Methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD), mescaline, and ibogaine.
  • PharmaTher and MediSynergics will initially collaborate to advance the research of MediSynergics patented ketamine derivatives as an alternative to opioid medications for pain disorders using predictive preclinical animal models.
  • Efficacy of the patented ketamine derivatives were demonstrated to be comparable or better than ketamine when tested in a murine capsaicin inflammatory pain model.
  • Fabio Chianelli, Chief Executive Officer of PharmaTher, said, We are excited to work with MediSynergics in the discovery and development of novel psychedelic derivatives and formulations for pain and CNS disorders.

NeonMind Announces Creation of Medical Clinics Advisory Board to Guide Planning and Operation of Company-Branded Clinics Across Canada

Retrieved on: 
Wednesday, May 26, 2021
Psychoactive drugs, Drugs, Health, Arylcyclohexylamines, Dissociative drugs, Ketones, Nicotinic antagonists, Sedatives, Esketamine, Clinic, Ketamine, Mental health

Members of the advisory board will be comprised of experts on provincial and local health care access and advocacy, ketamine treatment and psychotherapy protocols, and clinical operations, strategy, and growth.

Key Points: 
  • Members of the advisory board will be comprised of experts on provincial and local health care access and advocacy, ketamine treatment and psychotherapy protocols, and clinical operations, strategy, and growth.
  • To view an enhanced version of this image, please visit:
    "The formation of our Medical Clinic Advisory Board is a critical next step in the creation of our clinics and treatment models.
  • Currently, ketamine and esketamine may legally be prescribed and administered in Canadian medical clinics, however there is a need for these clinics and treatments to be tailored to community and local health needs.
  • NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System

Retrieved on: 
Monday, May 24, 2021
Psychoactive drugs, Branches of biology, Drugs, NMDA receptor antagonists, Iboga, Opioid antagonists, Drug rehabilitation, Nicotinic antagonists, Noribogaine, Ibogaine, Drug delivery

MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.

Key Points: 
  • MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.
  • The BTLS technology is an innovative drug delivery system designed to allow the targeted delivery of active pharmaceutical ingredients (APIs) through the Blood Brain Barrier.
  • Nextage CEO, Mr. Abraham Dreazen, said "Our innovative delivery technology has potential to revolutionize brain and CNS treatment.
  • Nextage is pioneering these emerging technologies in Israel and we look forward to working with MindMed and forming a long and successful collaboration."

/R E P E A T -- Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia's Symposium on Rapid Acting Anti-Depressants/

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, General anesthetics, NMDA receptor antagonists, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Ketamine, Esketamine, Mental disorder

"With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.

Key Points: 
  • "With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.
  • Braxia Scientific will play a vital role in translating and implementing the latest research for psychedelic, ketamine and esketamine therapies for persons with depression and related disorders.
  • Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods.
  • These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, NMDA receptor antagonists, Antidepressants, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Esketamine, Ketamine, Amyotrophic lateral sclerosis

as a scientific and clinical advisor for PharmaTher\xe2\x80\x99s clinical research programs involving ketamine as a potential treatment for major depressive disorders and amyotrophic lateral sclerosis (\xe2\x80\x9cALS\xe2\x80\x9d or \xe2\x80\x9cLou Gehrig\xe2\x80\x99s Disease\xe2\x80\x9d).\nMatthew Macaluso, D.O.

Key Points: 
  • as a scientific and clinical advisor for PharmaTher\xe2\x80\x99s clinical research programs involving ketamine as a potential treatment for major depressive disorders and amyotrophic lateral sclerosis (\xe2\x80\x9cALS\xe2\x80\x9d or \xe2\x80\x9cLou Gehrig\xe2\x80\x99s Disease\xe2\x80\x9d).\nMatthew Macaluso, D.O.
  • Professor Macaluso is also the Clinical Director of the UAB Depression and Suicide Center.
  • Matt has extensive experience in conducting clinical studies involving depression, including being a principal investigator of clinical studies involving esketamine which led to an FDA approval.
  • He is also a co-inventor for the novel use of ketamine as a potential treatment for ALS.

Update for Patient Access Solutions Opening and Managing New Center in Long Island, N.Y.

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Health sciences, Drugs, Arylcyclohexylamines, Ketones, Muscarinic antagonists, Nicotinic antagonists, Sedatives, Therapy, Ketamine, Mental health

In addition to strategic relations efforts, PASO is aggressively moving forward into the exciting new area of Biological Mental health solutions.

Key Points: 
  • In addition to strategic relations efforts, PASO is aggressively moving forward into the exciting new area of Biological Mental health solutions.
  • To add value and experience to our Ketamine Therapy product offering, PASO has engaged in ongoing discussions with one of the country\xe2\x80\x99s leading Ketamine Therapy Clinic Companies.
  • A psychiatrist referral is also required.\nAfter an initial consultation, patients will be set up into a 6-9 session program.
  • This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of Patient Access Solutions Inc. Securities and Exchange Commission filings available at http://www.sec.gov .\n'

Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia's Symposium on Rapid Acting Anti-Depressants

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, General anesthetics, NMDA receptor antagonists, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Ketamine, Esketamine, Mental disorder

"With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.

Key Points: 
  • "With Braxia Scientific\'s knowledge base, we have a tremendous opportunity to radically improve the quality of care patients receive.
  • Braxia Scientific will play a vital role in translating and implementing the latest research for psychedelic, ketamine and esketamine therapies for persons with depression and related disorders.
  • Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods.
  • These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.